Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 07:48:20 UTC - HELPFUL

Rated by Participant: 98958898A56F7559C5A8BFA8812756B014D529F2143616030E94920D41F76E3D
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 98958898A56F7559C5A8BFA8812756B014D529F2143616030E94920D41F76E3D
createdAtMillis - 1688888900242
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 1
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 167780323307752243298958898A56F7559C5A8BFA8812756B014D529F2143616030E94920D41F76E3D